A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

The new drugs delamanid and bedaquiline are increasingly used to treat multidrug-resistant
(MDR-) and extensively drug-resistant tuberculosis (XDR-TB). As evidence is lacking, the …

It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each
year. In spite of these numbers, children and adolescents have limited access to the new …

Clofazimine has been repurposed for the treatment of tuberculosis, especially for multidrug-
resistant tuberculosis (MDR-TB). To test the susceptibility to clofazimine of Mycobacterium …

Background The emergence of programmatically incurable tuberculosis threatens to
destabilise control efforts. The aim of this study was to collect prospective patient-level data …

The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build
an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant …

We assessed the effectiveness and safety of standardised, shorter multidrug-resistant
tuberculosis (MDR-TB) regimens by pooling data from observational studies. Published …

Although clofazimine is used to treat multidrug-resistant tuberculosis (MDR-TB), there is
scant information on its effectiveness and safety. The aim of this retrospective, observational …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue
to be challenging at both the patient and programme level. The World Health Organization …